文献速递银屑病与炎症性皮肤病

阿达木单抗治疗儿童重度斑块状银屑病的长期疗效与安全性

Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
PubMed 文献 · Br J Dermatol · 2019-07-25

该研究为随机双盲III期试验的52周长期扩展期,评估阿达木单抗在4-18岁重度斑块状银屑病患儿中的长期疗效与安全性。结果显示PASI 75应答率维持或改善,未发现新的安全风险。

要点

  • 长期扩展期未发生严重感染,未发现新的安全风险
  • 甲氨蝶呤转换为阿达木单抗后疗效可维持或提升

核心结论

  • 4-18岁重度斑块状银屑病患儿接受阿达木单抗治疗52周后,疾病严重程度降低且疗效维持或进一步改善,未发现新的安全风险。

研究设计与样本

  • 随机、双盲、双模拟III期试验的52周长期扩展期(LTE),纳入114例4-18岁重度斑块状银屑病患者,108例进入LTE。

主要发现

  • LTE期间未发生严重感染。

关键数值与推荐

  • 疗效以PASI 75(较基线改善≥75%)评估,各剂量组应答率范围如上。

临床怎么用

  • 甲氨蝶呤治疗后可考虑转换为阿达木单抗,转换后疗效可维持或提升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adalimumab (ADA) (Humira® , AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis. OBJECTIVES: To evaluate the long-term efficacy and safety of ADA in children with severe plaque psoriasis. METHODS: Results are presented from the 52-week long-term extension (LTE) of the randomized, double-blind, double-dummy, phase III trial, in children with severe plaque psoriasis (results from prior periods have been published). Patients aged ≥ 4 and < 18 years were randomized 1 : 1 : 1 to ADA 0·8 mg kg-1 (40 mg maximum) or 0·4 mg kg-1 (20 mg maximum) every other week or to methotrexate (MTX) 0·1-0·4 mg kg-1 (25 mg maximum) weekly. The 16-week initial treatment (IT) period was followed by a 36-week withdrawal period and a 16-week retreatment period. Patients could enter the LTE at prespecified time points to receive ADA 0·8 mg kg-1 (blinded or open label) or ADA 0·4 mg kg-1 (blinded), or to remain off treatment. Efficacy is reported for patient groups according to doses received in the IT and LTE periods. RESULTS: Of the 114 patients randomized in the IT period, 108 entered the LTE (n = 36 in each group); 93 received ADA 0·8 mg kg-1 . Efficacy (≥ 75% improvement from baseline in Psoriasis Area and Severity Index) was maintained or improved from entry to the end of the LTE: MTX(IT)/ADA 0·8(LTE) 31-86% of patients; ADA 0·4(IT)/0·4 or 0·8(LTE) 28-47%; ADA 0·8(IT)/0·8(LTE) 50-72%. No serious infections occurred in the LTE. CONCLUSIONS: After 52 weeks of long-term ADA treatment in children aged 4-18 years with severe plaque psoriasis, disease severity was reduced and maintained or further improved, as demonstrated by efficacy outcomes. No new safety risks were identified. What's already known about this topic? The results from the first three periods of this phase III trial in children aged 4-18 years with severe plaque psoriasis suggest that adalimumab is a safe and efficacious treatment option in this population. What does this study add? This is the first study to evaluate long-term treatment of adalimumab in children with severe psoriasis, and the first to evaluate switching from methotrexate to adalimumab in this population.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thaçi D, Papp K, Marcoux D, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019. PMID: 31017657. doi:10.1111/bjd.18029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。